MUNICH — Details of the ERA 223 clinical trial that led to a restriction in Europe of the use of the radiopharmaceutical radium-223 dichloride (Ra-223; Xofigo, Bayer) have now been presented here at ...

Editor's note: On July 17, 2018, this story was updated to include additional information on the drug's indication as well as contraindications with other drugs. PRAC first noted concerns about this ...

Scientists need a better understanding of the chemistry of radium to be able to target the isotope radium-223 (Ra-223) to cancer cells. Once delivered, Ra-223 can destroy those cells with alpha ...

Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared ...

Osteomimicry may contribute to the uptake of radium-223 within bone metastases and may subsequently enhance the therapeutic benefit of radium-223, according to an abstract presented by Andrew ...

The administration of Pluvicto within six months of radium-223 treatment proved to be safe and efficacious in patients with metastatic castration-resistant prostate cancer, research showed. Patients ...

Bone-only, osteoblastic disease and the absence of prior ARPI exposure define the optimal radium-223 candidate, while sequencing relative to lutetium-177 PSMA-617 remains an active area of ...

Table 1. Clinical Characteristics of Patients Eligible versus Optimal for Radium 223 A significant increase in overall survival was observed across all patients treated with radium 223 (hazard ratio ...

A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). This is an ...

A phase 2 trial showed that olaparib plus radium 223 prolonged progression-free survival in a subset of patients with castration-resistant prostate cancer and bone metastases. Radiographic progression ...

The high risk of bone involvement in cases of hormone-refractory prostate cancer has previously been treated with bisphosphonates (which reduce the risk of skeletal events but do not extend survival) ...